公开(公告)号：US20130011366A1

公开(公告)日：2013-01-10

申请号：US13604645

申请日：2012-09-06

Applicant: Masaji Okada ,  Yasushi Takamori ,  Kazuyuki Ogawa ,  Kinya Nagata

Inventor： Masaji Okada ,  Yasushi Takamori ,  Kazuyuki Ogawa ,  Kinya Nagata

IPC: A61K38/17 ,  A61P31/06 ,  C12N15/63 ,  A61K38/20 ,  A61K48/00

CPC classification number: A61K38/20 ,  A61K38/164 ,  A61K38/1709 ,  A61K38/1729 ,  A61K38/204 ,  A61K38/208 ,  A61K39/04 ,  A61K2300/00

Abstract: (Problems)To provide a therapeutic agent for infections comprising granulysin as an active ingredient which has little side effect and no cytotoxicity and to which bacteria can hardly acquire resistance, and a treatment method using the same.(Means for solving problems)The present invention provides a therapeutic agent for infections comprising as active ingredient: 15K granulysin, a combination of 15K granulysin and 15K granulysin in vivo expression vector, a combination of 15K granulysin and at least one interleukin selected from IL-6, IL-23 or IL-27, a combination of 15K granulysin in vivo expression vector and at least one interleukin selected from IL-6, IL-23 or IL-27, or a combination of 15K granulysin in vivo expression vector and HSP65DNA and IL-12DNA in vivo expression vector, which enhances killing effects on bacteria and has less side effect, and to which bacteria can hardly acquire resistance, and a treatment method using the same.

Abstract translation: （问题）为了提供包含颗粒溶素作为活性成分的感染治疗剂，其副作用小，无细胞毒性，细菌几乎不能获得抗性，以及使用该治疗剂的治疗方法。 （解决问题的手段）本发明提供一种感染用治疗剂，其包含作为活性成分的15K颗粒溶素，15K颗粒溶素和15K颗粒溶素在体内表达载体的组合，15K颗粒溶素与至少一种选自IL- 6，IL-23或IL-27，15K颗粒溶素在体内表达载体和选自IL-6，IL-23或IL-27中的至少一种白介素或15K颗粒溶素的体内表达载体和HSP65DNA的组合的组合 和IL-12DNA体内表达载体，其对细菌的杀伤作用增强，副作用较小，细菌几乎不能获得抗性，以及使用其的处理方法。

公开(公告)号：US20120288504A1

公开(公告)日：2012-11-15

申请号：US13511390

申请日：2010-11-24

Applicant: Jeffrey T.L. Smith

Inventor： Jeffrey T.L. Smith

IPC: A61K39/395 ,  A61K31/7105 ,  A61P35/02 ,  A61P7/02 ,  A61P35/00 ,  A61K31/7088 ,  A61K38/02

CPC classification number: A61K39/3955 ,  A61K31/454 ,  A61K38/2013 ,  A61K38/208 ,  A61K45/06 ,  A61K49/0004 ,  A61K49/0058 ,  A61K51/1033 ,  A61K2039/505 ,  A61K2039/545 ,  C07K16/248 ,  C07K16/462 ,  C07K2317/24 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/41 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/90 ,  C07K2317/92 ,  C07K2317/94 ,  G01N33/6863 ,  Y02A50/412 ,  Y02A50/58

Abstract: The present invention is directed to therapeutic methods using IL-6 antagonists such as antibodies and fragments thereof having binding specificity for IL-6 to prevent or treat thrombosis or hypercoagulation in patients having, or at risk of developing, diseases associated with abnormal blood coagulation or fibrinolysis and/or patients which are at increased risk or are being treated by a regimen that renders the patient at increased susceptibility to hypercoagulation or thrombosis such as patients who have previously had a stroke or heart attack or persons on a treatment regimen with a drug or chemotherapy and/or radiation that is associated with increased risk of thrombosis or hypercoagulation. In preferred embodiments these patients will comprise those exhibiting elevated D-dimer or other coagulation cascade related proteins and optionally will further exhibit elevated C reactive protein prior to treatment. The subject therapies also may include the administration of other actives such as chemotherapeutics, anti-coagulants, statins, et al.

Abstract translation: 本发明涉及使用IL-6拮抗剂如具有对IL-6具有结合特异性的抗体及其片段的预防或治疗血栓形成或高凝状态的患者的治疗方法，所述患者具有发生与异常血液凝固相关的疾病或有发展的风险，或 纤维蛋白溶解和/或风险增高的患者或正在通过使患者对高凝或血栓形成敏感性增加的方案进行治疗，例如先前患有中风或心脏病发作的患者或患有药物治疗方案的患者，或 与血栓形成或凝血增加风险相关的化学疗法和/或辐射。 在优选实施方案中，这些患者将包括那些表现出升高的D-二聚体或其他凝血级联相关蛋白的那些，并且任选地将在治疗之前进一步显示升高的C反应蛋白。 主题疗法还可以包括施用其它活性物质，例如化学治疗剂，抗凝血剂，他汀类药物等。

公开(公告)号：US08298549B2

公开(公告)日：2012-10-30

申请号：US12651836

申请日：2010-01-04

Applicant: Joseph P. Balint ,  Frank R. Jones ,  Richard B. Gayle, III

Inventor： Joseph P. Balint ,  Frank R. Jones ,  Richard B. Gayle, III

IPC: A61K39/235 ,  C12N15/861

CPC classification number: A61K39/12 ,  A61K38/191 ,  A61K38/193 ,  A61K38/2013 ,  A61K38/2026 ,  A61K38/2033 ,  A61K38/204 ,  A61K38/2046 ,  A61K38/2066 ,  A61K38/208 ,  A61K38/217 ,  A61K39/00 ,  A61K39/0011 ,  A61K39/21 ,  A61K39/235 ,  A61K2039/5256 ,  A61K2039/54 ,  A61K2039/545 ,  A61K2039/55555 ,  A61K2039/57 ,  A61K2039/575 ,  C07K14/005 ,  C07K14/70503 ,  C07K14/71 ,  C12N15/86 ,  C12N2710/10034 ,  C12N2710/10321 ,  C12N2710/10334 ,  C12N2710/10343 ,  C12N2710/10371 ,  C12N2710/20034 ,  C12N2740/15034 ,  C12N2740/16234 ,  C12N2800/24

Abstract: Methods for generating immune responses using adenovirus vectors that allow multiple vaccinations with the same adenovirus vector and vaccinations in individuals with preexisting immunity to adenovirus are provided.

Abstract translation: 提供了使用允许使用相同腺病毒载体进行多次疫苗接种的腺病毒载体产生免疫反应的方法，并且在具有预先存在的腺病毒免疫的个体中接种疫苗。

公开(公告)号：US20120148528A1

公开(公告)日：2012-06-14

申请号：US13291838

申请日：2011-11-08

Applicant: David W.H. Riches ,  Alison Bamberg

Inventor： David W.H. Riches ,  Alison Bamberg

IPC: A61K38/19 ,  A61P17/02 ,  A61P35/00 ,  A61P7/00 ,  A61K38/21 ,  A61K38/20

CPC classification number: A61K38/191 ,  A61K31/713 ,  A61K38/2006 ,  A61K38/208 ,  A61K38/217

Abstract: Embodiments herein concern compositions and methods for treating a subject having or suspected of developing a pulmonary disorder or cancer. Certain embodiments concern modulating protein tyrosine phosphatase non-receptor type 13 (PTPN13) expression and/or activity in a subject to treat uncontrolled cellular growth in the subject.

Abstract translation: 本文的实施方案涉及用于治疗患有或怀疑发展为肺病或癌症的受试者的组合物和方法。 某些实施方案涉及调节受试者中的蛋白酪氨酸磷酸酶非受体13型（PTPN13）表达和/或活性以治疗受试者中不受控制的细胞生长。

公开(公告)号：US20120107282A1

公开(公告)日：2012-05-03

申请号：US13247567

申请日：2011-09-28

Applicant: Seung U. Kim

Inventor： Seung U. Kim

IPC: A61K35/12 ,  A61P35/00 ,  A61K31/513

CPC classification number: A61K31/513 ,  A61K35/30 ,  A61K38/2026 ,  A61K38/208 ,  A61K38/215 ,  A61K38/45 ,  A61K38/465 ,  A61K38/50 ,  C12N5/0618 ,  C12N2510/00 ,  C12Y207/01021 ,  C12Y301/01001 ,  C12Y305/04001

Abstract: Disclosed is a method of treatment of an individual suffering from primary brain tumors (glioma and medulloblastoma) and brain metastases of extracranial cancers using human stem cells encoding therapeutic genes. The method includes giving the individual a clinically acceptable therapeutic reagent by intravascular injection of a pharmaceutical composition. The pharmaceutical composition includes neural stem cells (NSCs) genetically engineered to express a suicide gene (cytosine deaminase) and a cytokine gene (IFN-β) and a pharmaceutical carrier suitable for injection. The NSCs migrate selectively to tumor site in the brain, target tumor cells, kill tumor cells, inhibit tumor growth and thus treat the tumor.

Abstract translation: 公开了使用编码治疗基因的人干细胞治疗患有原发性脑肿瘤（神经胶质瘤和成神经管细胞瘤）的个体和颅外癌的脑转移的方法。 该方法包括通过血管内注射药物组合物给予个体临床可接受的治疗试剂。 该药物组合物包括遗传工程化以表达自杀基因（胞嘧啶脱氨酶）和细胞因子基因（IFN-α）的神经干细胞（NSCs）和适合于注射的药物载体。 NSCs选择性地迁移到脑中的肿瘤部位，靶肿瘤细胞，杀死肿瘤细胞，抑制肿瘤生长，从而治疗肿瘤。

公开(公告)号：US20120021996A1

公开(公告)日：2012-01-26

申请号：US13250141

申请日：2011-09-30

Applicant: Pramod K. Srivastava ,  Zihai Li

Inventor： Pramod K. Srivastava ,  Zihai Li

IPC: A61K38/17 ,  A61P35/00

CPC classification number: A61K38/1709 ,  A61K31/135 ,  A61K31/196 ,  A61K31/277 ,  A61K31/353 ,  A61K31/395 ,  A61K31/495 ,  A61K31/506 ,  A61K31/675 ,  A61K31/7048 ,  A61K38/17 ,  A61K38/208 ,  A61K39/0011 ,  A61K39/385 ,  A61K39/39558 ,  A61K45/06 ,  A61K2039/6043 ,  A61N5/10 ,  Y02A50/386 ,  Y02A50/401 ,  Y02A50/403 ,  Y02A50/407 ,  Y02A50/41 ,  Y02A50/412 ,  Y02A50/466 ,  A61K2300/00

Abstract: The present invention relates to methods of improving a treatment outcome comprising administering a heat shock protein (HSP) preparation or an α-2-macroglobulin (α2M) preparation with a non-vaccine treatment modality. In particular, an HSP preparation or an α2M preparation is administered in conjunction with a non-vaccine treatment modality for the treatment of cancer or infectious diseases. In the practice of the invention, a preparation comprising HSPs such as but not limited to, hsp70, hsp90 and gp96 alone or in combination with each other, noncovalently or covalently bound to antigenic molecules or α2M, noncovalently or covalently bound to antigenic molecules is administered in conjunction with a non-vaccine treatment modality.

Abstract translation: 本发明涉及改善治疗结局的方法，包括以非疫苗治疗方式施用热休克蛋白（HSP）制剂或α-2-巨球蛋白（α2M）制剂。 特别地，HSP制剂或α2M制剂与用于治疗癌症或感染性疾病的非疫苗治疗方式联合施用。 在本发明的实践中，给予非共价或共价结合抗原分子或非共价结合于抗原分子的α2M的HSP（例如但不限于hsp70，hsp90和gp96）或彼此组合的制剂，其非共价或共价结合， 结合非疫苗治疗方式。

公开(公告)号：US20110311554A1

公开(公告)日：2011-12-22

申请号：US13224959

申请日：2011-09-02

Applicant: Richard Gomer ,  Darrell Pilling

Inventor： Richard Gomer ,  Darrell Pilling

IPC: A61K39/395 ,  A61P27/02

CPC classification number: G01N33/505 ,  A61K31/13 ,  A61K31/66 ,  A61K31/729 ,  A61K38/1709 ,  A61K38/208 ,  A61K38/39 ,  G01N33/5047 ,  Y02A50/401 ,  Y02A50/423 ,  Y02A50/57 ,  Y10S514/885 ,  A61K2300/00

Abstract: The present invention relates to the ability of anti-FcγR antibodies to suppress fibrocytes. Methods and compositions for suppressing fibrocytes are provided. These methods are useful in a variety of applications including treatment and prevention of conditions resulting from fibrosis in the liver, kidney, lung, heart and pericardium, eye, skin, mouth, pancreas, gastrointestinal tract, brain, breast, bone marrow, bone, genitourinary system, a tumor, or a wound.

Abstract translation: 本发明涉及抗FcγR抗体抑制纤维细胞的能力。 提供了抑制纤维细胞的方法和组合物。 这些方法可用于各种应用，包括治疗和预防肝，肾，肺，心脏和心包，眼睛，皮肤，口腔，胰腺，胃肠道，脑，乳腺，骨髓，骨骼中的纤维化引起的病症， 泌尿生殖系统，肿瘤或伤口。

公开(公告)号：US20110274649A1

公开(公告)日：2011-11-10

申请号：US13099235

申请日：2011-05-02

Applicant: Thomas S. Kupper ,  Luzheng Liu ,  Rachael A. Clark

Inventor： Thomas S. Kupper ,  Luzheng Liu ,  Rachael A. Clark

IPC: A61K45/00 ,  A61K39/275 ,  A61K39/285 ,  A61P35/00 ,  A61P31/12 ,  A61P31/18 ,  A61P31/16 ,  A61P31/14 ,  A61P31/10 ,  A61P33/02 ,  A61P33/06 ,  A61P31/06 ,  A61P31/04 ,  C12N7/00 ,  A61M37/00 ,  A61K39/12

CPC classification number: C12N15/86 ,  A61K38/177 ,  A61K38/18 ,  A61K38/1825 ,  A61K38/19 ,  A61K38/193 ,  A61K38/20 ,  A61K38/2006 ,  A61K38/2013 ,  A61K38/2046 ,  A61K38/208 ,  A61K38/2086 ,  A61K39/12 ,  A61K39/285 ,  A61K2039/5254 ,  A61K2039/5256 ,  A61K2039/54 ,  C12N2710/24134 ,  C12N2710/24143 ,  Y02A50/386 ,  Y02A50/394 ,  Y02A50/403 ,  Y02A50/41 ,  Y02A50/412 ,  Y02A50/478 ,  Y02A50/484

Abstract: Attenuated, replication-deficient viruses such as vaccinia viruses are used to deliver an exogenous viral, bacterial, parasitic or tumor antigen to an epidermal tissue such as the skin, lungs or gastrointestinal tract, which has been mechanically disrupted, in an amount effective to elicit or stimulate a cell mediated immune response. The epidermal tissue may be mechanically disrupted by a device such as a scarification needle or an abrader device. The epidermis may be mechanically disrupted prior to, at the same time, or immediately after the administration of the vaccine. The vaccine can be used to induce immunity against a pathogen, such as a virus, bacteria, or parasite, or against a cancer in a subject that has or is at risk of developing cancer. In some embodiments a co-stimulatory molecule, a growth factor, an adjuvant and/or a cytokine is administered before, with or after the viral vaccine. In some embodiments, the co-stimulatory molecule is co-expressed with the antigen by the virus.

Abstract translation: 减毒的复制缺陷型病毒如痘苗病毒用于将外源性病毒，细菌，寄生虫或肿瘤抗原递送至已被机械破坏的表皮组织如皮肤，肺或胃肠道，其数量有效引出 或刺激细胞介导的免疫应答。 表皮组织可能被诸如刮痕针或磨擦装置之类的装置机械地破坏。 在施用疫苗之前，同时或之后，表皮可能被机械破坏。 该疫苗可以用于诱导针对病原体（例如病毒，细菌或寄生虫）或具有发生癌症风险的受试者中的癌症的免疫。 在一些实施方案中，在病毒疫苗之前，之中或之后施用共刺激分子，生长因子，佐剂和/或细胞因子。 在一些实施方案中，共刺激分子与病毒与抗原共表达。

公开(公告)号：US20110206635A1

公开(公告)日：2011-08-25

申请号：US13076365

申请日：2011-03-30

Applicant: Tingchao CHEN ,  Yi Zhao ,  W. French Anderson

Inventor： Tingchao CHEN ,  Yi Zhao ,  W. French Anderson

IPC: A61K38/20 ,  A61P31/12

CPC classification number: A61K38/208 ,  A61K31/675 ,  A61K38/193 ,  A61K45/06 ,  A61N5/10 ,  A61N2005/1098 ,  C07K14/53 ,  C07K14/5434 ,  A61K2300/00

Abstract: Methods for enhancing or stimulating hematopoiesis including the step of administering Interleukin-12 (IL-12) to yield hernatopoietic recovery in a mammal in need. Preferred methods include the step of administering IL-12 as an adjuvant therapy to alleviate the hematopoietic toxicities associated with one or more treatment regimens used to combat a disease state. Other methods include administering IL-12 to ameliorate various hematopoietic deficiencies. Still other methods are directed to uses of IL-12 for in-vivo proliferation of hematopoietic repopulating cells, hematopoietic progenitor cells and hematopoietic stem cells. Other disclosed methods are directed to uses of IL-12 for bone marrow preservation or recovery.

Abstract translation: 用于增强或刺激造血的方法，包括施用白细胞介素-12（IL-12）以在需要的哺乳动物中产生愈伤组织的恢复的步骤。 优选的方法包括施用IL-12作为辅助治疗以减轻与用于对抗疾病状态的一种或多种治疗方案相关的造血毒性的步骤。 其他方法包括给予IL-12以改善各种造血缺陷。 还有其它方法涉及IL-12用于造血再生细胞，造血祖细胞和造血干细胞的体内增殖的用途。 其他公开的方法涉及IL-12用于骨髓保存或恢复的用途。

公开(公告)号：US20110195045A1

公开(公告)日：2011-08-11

申请号：US12930592

申请日：2011-01-11

Applicant: Emmanuelle Godefroy ,  Francine Jotereau ,  Nina Bhardwaj

Inventor： Emmanuelle Godefroy ,  Francine Jotereau ,  Nina Bhardwaj

IPC: A61K39/00 ,  A61K38/20 ,  C12Q1/02 ,  G01N33/53 ,  C07K7/08 ,  A61K35/12 ,  A61P35/00 ,  A61P37/04

CPC classification number: G01N33/56977 ,  A61K38/005 ,  A61K38/208 ,  A61K39/0011 ,  A61K2039/572 ,  C07K2319/01 ,  C07K2319/33 ,  C07K2319/55 ,  C12N9/6491 ,  G01N33/5743 ,  G01N2800/52

Abstract: The present invention relates to enhancing, modulating or stimulating the immune response to MMP-2 expressing tumors, including melanoma, and to the modulation and application of immune modulators and MMP-2 peptides for melanoma or other MMP-2 expressing tumor vaccines. The invention provides methods and means to activate an effective response to MMP-2 expressing tumors and modulate the ability of MMP-2 to skew CD4+ T cell responses toward that of TH2 cells, which are less effective mediators of tumor cell clearance than TH1 cells. Methods and assays are provided for screening for compounds, agents, or peptides capable of enhancing or activating immune responses, particularly to melanoma.

Abstract translation: 本发明涉及增强，调节或刺激对表达MMP-2的肿瘤（包括黑素瘤）的免疫应答，以及用于黑素瘤或其他MMP-2表达肿瘤疫苗的免疫调节剂和MMP-2肽的调节和应用。 本发明提供了激活对表达MMP-2的肿瘤的有效反应的方法和手段，并且调节MMP-2相对于TH2细胞倾斜CD4 + T细胞应答的能力，TH2细胞与TH1细胞相比是较不有效的肿瘤细胞清除介质。 提供了用于筛选能够增强或激活免疫应答，特别是黑素瘤的化合物，试剂或肽的方法和试验。